Edition:
United Kingdom

Merck KGaA (MRCG.DE)

MRCG.DE on Xetra

90.66EUR
13 Dec 2017
Change (% chg)

-- (--)
Prev Close
€90.66
Open
--
Day's High
--
Day's Low
--
Volume
--
Avg. Vol
572,214
52-wk High
€115.20
52-wk Low
€87.23

Select another date:

Mon, Dec 11 2017

BRIEF-Merck Signs Distribution Agreement With Avanti Polar Lipids

* MERCK SIGNS DISTRIBUTION AGREEMENT WITH AVANTI POLAR LIPIDS Source text for Eikon: Further company coverage:

BRIEF-Merck KGaA ‍Receives Approval (Updated Registration) For Cladribine Tablets In Australia​

* SAYS ‍RECEIVES APPROVAL (UPDATED REGISTRATION) FOR CLADRIBINE TABLETS IN AUSTRALIA​ Source text for Eikon: Further company coverage:

BRIEF-Merck Says Anand Nambiar, MD, Assigned As Head Of Integrated Circuit Materials Unit Of Merck KGaA

* SAYS ANAND NAMBIAR, MD, HAS ACCEPTED NEW ASSIGNMENT AS 'HEAD OF INTEGRATED CIRCUIT MATERIALS' UNIT OF MERCK KGAA

BRIEF-Merck KGAA, Darmstadt Announces FDA 510(K) Clearance Of Genea Biomedx’S Fertility Benchtop Incubator Geri

* MERCK KGAA, DARMSTADT, GERMANY ANNOUNCES FDA 510(K) CLEARANCE OF PARTNER GENEA BIOMEDX’S FERTILITY BENCHTOP INCUBATOR GERI™

BRIEF-Merck KgaA Says FDA 510(K) Clearance Of Benchtop Embryo Incubator Geri

* ANNOUNCES FDA 510(K) CLEARANCE OF PARTNER GENEA BIOMEDX’S FERTILITY BENCHTOP INCUBATOR GERI

Nestle, Stada prepare rival bids for Germany's Merck consumer health: sources

LONDON/FRANKFURT Swiss food giant Nestle and the private equity owners of German drug firm Stada are both preparing tentative bids for Merck KgaA's consumer health unit, several sources told Reuters.

Nestle, Stada prepare rival bids for Germany's Merck consumer health - sources

LONDON/FRANKFURT Swiss food giant Nestle and the private equity owners of German drug firm Stada are both preparing tentative bids for Merck KgaA's consumer health unit, several sources told Reuters.

Nestle, Stada prepare rival bids for Germany's Merck consumer health - sources

LONDON/FRANKFURT, Nov 30 Swiss food giant Nestle and the private equity owners of German drug firm Stada are both preparing tentative bids for Merck KgaA's consumer health unit, several sources told Reuters.

Merck KGaA, Pfizer's immunotherapy fails in gastric cancer trial

FRANKFURT Germany's Merck KGaA has suffered a setback in the development of key cancer immunotherapy Bavencio, it having failed in a trial to prolong lives in gastric cancer patients when compared with standard chemotherapy.

UPDATE 2-Merck KGaA, Pfizer's immunotherapy fails in gastric cancer trial

* Results from use against lung cancer still outstanding (Adds share price, analyst's comment)

Select another date: